abiraterone has been researched along with gsk2879552 in 1 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (gsk2879552) | Trials (gsk2879552) | Recent Studies (post-2010) (gsk2879552) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 29 | 2 | 26 |
| Protein | Taxonomy | abiraterone (IC50) | gsk2879552 (IC50) |
|---|---|---|---|
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | 0.2407 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, IC; Chen, MC; Hsieh, CM; Hsu, KC; Lai, RW; Lin, TE; Liou, JP; Nepali, K; Ojha, R; Pan, SL | 1 |
1 other study(ies) available for abiraterone and gsk2879552
| Article | Year |
|---|---|
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
Topics: Antineoplastic Agents; Histone Deacetylase Inhibitors; Histone Demethylases; Humans; Male; Pargyline; Prostatic Neoplasms | 2021 |